BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Drug-Drug Interaction Study With Rifampin
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT01002079
- Locations
- 🇮🇳
Local Institution, Bangalore, India
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT00996879
- Locations
- 🇺🇸
Wcct Global, Llc, Cypress, California, United States
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT00990912
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 108
- Registration Number
- NCT00989235
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Phase 4
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00986778
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00983957
- Locations
- 🇺🇸
MDS Pharma Services (US), Inc, Tempe, Arizona, United States
🇺🇸Covance Clinical Research Unit, Inc., Austin, Texas, United States
🇨🇦Local Institution, St. Laurent, Quebec, Canada
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 238
- Registration Number
- NCT00982488
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸Ucla Department Of Medicine, Los Angeles, California, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00979316
- Locations
- 🇺🇸
Mds Pharma Services (Us), Inc, Tempe, Arizona, United States
Safety Study of BMS-816336 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DyslipidemiaDiabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00979368
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00978731
© Copyright 2025. All Rights Reserved by MedPath